{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:16:17Z","timestamp":1740104177569,"version":"3.37.3"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI000390-31"],"award-info":[{"award-number":["AI000390-31"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:label\/><jats:p>Hepatitis C (HCV) treatment for patients coinfected with human immunodeficiency virus (HIV) and HCV is associated with modest rates of sustained virologic response (SVR) and an increased rate of relapse when compared to HCV monoinfected patients. As patients who attain SVR and patients who relapse are clinically indistinguishable during treatment, where both groups have fully suppressed HCV viral load, it has not been possible to identify in advance those who will relapse. Biomarkers that may distinguish patients with differential treatment response may be clinically useful and provide insight into mechanisms of relapse. In this retrospective study, serum and PBMCs were obtained from 41 HIV\/HCV co\u2010infected patients and 17 healthy volunteers. Changes in antibody titers to various regions of the HCV proteome during treatment for HCV were determined using a novel luciferase immunoprecipitation assay. Changes in B\u2010cell subtypes in patients with differential treatment response as well as healthy volunteers were compared. This study demonstrates that elevated anti\u2010HCV core antibody titers persisted during HCV treatment in patients who relapsed when compared to those who attained SVR. Furthermore, characterization of B cells in patients who relapsed demonstrated an abnormal B\u2010cell phenotype distribution characterized by elevated frequencies of exhausted B cells among relapsers at baseline, which persisted despite suppression of HCV viremia at 24 weeks, along with increased frequencies of plasmablasts. These data suggest that anti\u2010HCV specific B cells may be responding to ongoing subclinical HCV replication in patients who will relapse. <jats:bold><jats:italic>J. Med. Virol. 87:544\u2013552, 2015<\/jats:italic>.<\/jats:bold> \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.24089","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T20:46:41Z","timestamp":1421873201000},"page":"544-552","source":"Crossref","is-referenced-by-count":1,"title":["Persistently elevated abnormal B\u2010cell subpopulations and anti\u2010core antibodies in patients co\u2010infected with HIV\/HCV who relapse"],"prefix":"10.1002","volume":"87","author":[{"given":"Anita","family":"Kohli","sequence":"first","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"},{"name":"Clinical Research Directorate\/Clinical Monitoring Research Program Leidos Biomedical Research Inc. (formerly SAIC\u2013Frederick, Inc.) Frederick National Laboratory for Cancer Research Frederick Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Funk","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Burbelo","sequence":"additional","affiliation":[{"name":"National Institute of Dental and Craniofacial Research National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Barrett","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric G.","family":"Meissner","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Santich","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashton","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Johl","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreetha","family":"Sidharthan","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Moir","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department National Institutes of Health Clinical Center Bethesda Maryland"},{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Fauci","sequence":"additional","affiliation":[{"name":"Laboratory of Immunoregulation National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01064-10"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/318501"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0mb00342e"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.11.140"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00476-09"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/655780"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/655780"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-96"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312942"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45685"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302062"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03432.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23136"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v8.i4.577"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","unstructured":"MallolasJ RiveroPS FainboimA CooperH SlimC ThompsonJ WahlS GreavesJ SulkowskiW.2012. Barcelona Spain Abstract Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co\u2010infected patients: End of treatment (week 48) interim results. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver April 18\u201322.","DOI":"10.1016\/S0168-8278(12)60064-6"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285528"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072683"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471d53"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32825eaba7"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23773"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-012-1418-4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/589718"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-331462"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/339042"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000879"},{"key":"e_1_2_7_33_1","unstructured":"SulkowskiMS SorianoSK RockstrohV DieterichJK GirardDT BsharatPM HenshawM RubinJ GargRA AddaV.2012. Telaprevir in combination with peginterferon alfa\u20102a\/ribavirin in HCV\/HIV co\u2010infected patients: SVR24 final study results. Program and abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases November 9\u201313 Boston Massachusetts Abstract 54."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07662"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1632"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.006"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24089","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T22:54:28Z","timestamp":1696460068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,21]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/jmv.24089"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24089","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2015,1,21]]}}}